Logo

Sanofi Signs an Exclusive Worldwide Collaboration Agreement with Skyhawk to Discover Novel Small Molecules for Oncology and Immunology Targets

Share this

Sanofi Signs an Exclusive Worldwide Collaboration Agreement with Skyhawk to Discover Novel Small Molecules for Oncology and Immunology Targets

Shots:

  • Skyhawk to receive $54M up front & is also eligible to receive ~$2B in milestones along with royalties on future sales
  • Sanofi gets an exclusive option to license global intellectual property rights for candidates directed to program targets that emerges from the collaboration & will be responsible for further development and commercialization
  • The companies will use Skyhawk's SkySTAR platform to discover and develop novel small molecules that modulate RNA splicing for oncology and immunology targets. SkySTAR platform combines computational biology techniques, kinetic models, and conformational structural models of RNA that help to develop therapies for disease targets that now have few or no therapeutic alternatives

Ref: PRNewswire | Image: Sanofi

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions